Avid Bioservices Q4 2024 GAAP EPS $(1.94) vs $(0.04) Estimate, Sales $43.000M Beat $42.142M Estimate

7/2/24 4:06:48 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CDMO alert in real time by email

Avid Bioservices (NASDAQ:CDMO) reported quarterly losses of $(1.94) per share which missed the analyst consensus estimate of $(0.04) by 4750 percent. The company reported quarterly sales of $43.000 million which beat the analyst consensus estimate of $42.142 million by 2.04 percent. This is a 8.04 percent increase over sales of $39.799 million the same period last year.

Get the next $CDMO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CDMO

Date	Price Target	Rating	Analyst
9/28/2023		Mkt Perform	William Blair
3/14/2023	$20.00	Sector Weight → Overweight	KeyBanc Capital Markets
3/9/2022	$31.00 → $28.00	Overweight	Stephens & Co.
12/8/2021	$29.00 → $35.00	Buy	Craig-Hallum
12/8/2021	$27.00 → $32.00	Outperform	RBC Capital
12/8/2021		Overweight → Sector Weight	Keybanc
6/30/2021	$21.00 → $29.00	Buy	Craig-Hallum
6/30/2021	$21.00 → $27.00	Outperform	RBC Capital

More analyst ratings

Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction
TUSTIN, Calif. and LONDON and BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) ("Avid" or the "Company"), a dedicated biologics contract development and manufacturing organization ("CDMO") working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, GHO Capital Partners LLP ("GHO") and Ampersand Capital Partners ("Ampersand") today announced they have entered into a definitive merger agreement for Avid to be acquired by funds managed by GHO and Ampersand in an all-cash transaction valued at approximately $1.1 billion. Under the terms of the merger agreement, GHO and Ampersand
11/6/24 6:04:07 PM ET
$CDMO
Biotechnology: Pharmaceutical Preparations
Health Care
Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference
TUSTIN, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the upcoming Craig-Hallum Bioprocessing Conference. Nick Green, president and chief executive officer, and Pramthesh Patel, Ph.D., vice president of process development, will be the featured speakers in a fireside chat at the conference, which will take place virtually on September 19, 2024. Details of the company's participati
9/12/24 4:05:27 PM ET
$CDMO
Biotechnology: Pharmaceutical Preparations
Health Care
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024
-- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million -- -- Maintained FY2025 Revenue Guidance of Between $160 Million and $168 Million -- TUSTIN, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the first quarter ended July 31, 2024. Highlights from the Quarter Ended July 31, 2024, and Other Events:
9/9/24 4:05:31 PM ET
$CDMO
Biotechnology: Pharmaceutical Preparations
Health Care

$CDMO
Financials

Live finance-specific insights

Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024
-- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million -- -- Maintained FY2025 Revenue Guidance of Between $160 Million and $168 Million -- TUSTIN, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the first quarter ended July 31, 2024. Highlights from the Quarter Ended July 31, 2024, and Other Events:
9/9/24 4:05:31 PM ET
$CDMO
Biotechnology: Pharmaceutical Preparations
Health Care
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024
TUSTIN, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2025 on September 9, 2024, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the first quarter and review recent corporate developments. To listen to the live webcast, or access the archived webcast, please
9/3/24 4:05:20 PM ET
$CDMO
Biotechnology: Pharmaceutical Preparations
Health Care
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024
-- Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History -- -- Signed $30 Million in Net New Business Resulting in Backlog of $193 Million -- -- New Mammalian and Cell and Gene Therapy Facilities Fully Operational and in Service; Capital Expenditure Associated with Three-Year Expansion Program Completed -- -- FY 2025 Revenue Guidance of Between $160 Million and $168 Million -- TUSTIN, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and ph
7/2/24 4:05:04 PM ET
$CDMO
Biotechnology: Pharmaceutical Preparations
Health Care

Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
NEW YORK, Dec. 1, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t
12/1/23 6:16:00 PM ET
$ALK
$ALKS
$AWI
$BLDR
Air Freight/Delivery Services
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care
STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors
DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal
5/3/23 4:30:00 PM ET
$CDMO
$STE
Biotechnology: Pharmaceutical Preparations
Health Care
Industrial Specialties
Avid Bioservices Appoints Oksana Lukash as Vice President, People
TUSTIN, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Oksana Lukash, as vice president, people. Ms. Lukash has more than 20 years of human resources experience with both established and entrepreneurial organizations across a range of industries. Prior to joining Avid, Ms. Lukash served as vice president, people & culture at Oncocyte Corporation, a precision diagnostics company. During her three year
11/16/22 8:05:00 AM ET
$CDMO
Biotechnology: Pharmaceutical Preparations
Health Care

Avid Bioservices Q4 2024 GAAP EPS $(1.94) vs $(0.04) Estimate, Sales $43.000M Beat $42.142M Estimate

Chat with this insight

Recent Analyst Ratings for $CDMO

$CDMO SEC Filings

SEC Form DEFA14A filed by Avid Bioservices Inc.

Avid Bioservices Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form DEFA14A filed by Avid Bioservices Inc.

$CDMO Press Releases

Fastest customizable press release news feed in the world

Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction

Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference

Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024

$CDMO Market Insights

Live Market Insights

Why Avid Bioservices Stock Is Moving Higher Wednesday

Avid Bioservices shares are trading higher after the company reported better-than-expected Q4 sales results.

RBC Capital Reiterates Outperform on Avid Bioservices, Maintains $8 Price Target

$CDMO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Hancock Richard B bought $202,036 worth of shares (38,803 units at $5.21), increasing direct ownership by 49% to 117,563 units (SEC Form 4)

Hancock Richard B converted options into 9,612 shares and bought $134,734 worth of shares (23,000 units at $5.86), increasing direct ownership by 71% to 78,760 units (SEC Form 4)

SEC Form 4: Carleone Joseph bought $190,696 worth of shares (20,000 units at $9.53), increasing direct ownership by 27% to 93,956 units

$CDMO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Commercial Officer Kwietniak Matthew R. converted options into 335 shares and sold $1,208 worth of shares (119 units at $10.15), increasing direct ownership by 0.86% to 25,407 units (SEC Form 4)

Chief Operations Officer Richieri Richard A. converted options into 5,968 shares and sold $22,432 worth of shares (2,232 units at $10.05), increasing direct ownership by 10% to 37,704 units (SEC Form 4)

Chief Commercial Officer Kwietniak Matthew R. converted options into 2,763 shares and sold $9,869 worth of shares (982 units at $10.05), increasing direct ownership by 8% to 25,191 units (SEC Form 4)

$CDMO Financials

Live finance-specific insights

Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024

Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024

Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024

$CDMO Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Avid Bioservices Inc.

Amendment: SEC Form SC 13G/A filed by Avid Bioservices Inc.

Amendment: SEC Form SC 13G/A filed by Avid Bioservices Inc.

$CDMO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$CDMO Leadership Updates

Live Leadership Updates

William Blair initiated coverage on Avid Bioservices

Avid Bioservices upgraded by KeyBanc Capital Markets with a new price target

Stephens & Co. reiterated coverage on Avid Bioservices with a new price target

Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors

Avid Bioservices Appoints Oksana Lukash as Vice President, People

Recent Analyst Ratings for
$CDMO

$CDMO
SEC Filings

$CDMO
Press Releases

$CDMO
Market Insights

$CDMO
Insider Purchases

$CDMO
Insider Trading

$CDMO
Financials

$CDMO
Large Ownership Changes

$CDMO
Analyst Ratings

$CDMO
Leadership Updates